Вы искали: nsf (Английский - Словенский)

nsf
no seč

n nsf (norges standardiseringsforbund)”
n nsf (norges standardiseringsforbund).‘

nephrogenic systemic fibrosis (nsf)
nefrogenična sistemska fibroza (nfs)

cases of nsf have also been reported in patients
zato se zdravilo optimark pri teh skupinah bolnikov ne sme uporabljati (glejte poglavje 4. 3).

nsf causes thickening of the skin and connective tissues.
nefrogena sistemska fibroza povzroča odebelitev kože in veznih tkiv.

nsf is a disease involving thickening of the skin and connective tissues.
nsf je bolezen, pri kateri se odebelijo koža in vezivna tkiva.

there is no evidence to support the initiation of haemodialysis for prevention or treatment of nsf in patients not already undergoing haemodialysis.
ni dokazov, ki bi podpirali uvedbo hemodialize za preprečevanje ali zdravljenje nsf pri bolnikih, ki se še ne zdravijo s hemodializo.

in addition, the company will provide annual reviews of cases of nsf and conduct a study on the accumulation of gadolinium in the bone.
poleg tega bo zagotovila letna poročila primerov nsf in izvedla študijo o kopičenju gadolinija v kosteh.

nsf may result in debilitating joint immobility, muscle weakness or impairment of the function of internal organs which may potentially be life threatening.
nsf lahko povzroči nepremičnost zaradi oslabitve sklepov, šibkost mišic ali okvaro delovanja notranjih organov, ki je lahko tudi smrtno nevarna.

there is no evidence to support the initiation of haemodialysis for prevention or treatment of nsf in patients not already undergoing haemodialysis.  children optimark must not be administered with an autoinjector.
ni dokazov, ki podpirajo uporabo hemodialize za preprečevanje ali zdravljenje nsf pri bolnikih, ki niso na hemodializi.  otroci zdravilo optimark se ne sme dajati z avtoinjektorjem.

nevertheless, because of reported cases of nsf that may be associated with renal impairment for other gadolinium containing contrast agents and for gadoversetamide, optimark should not be used in these patients.
zaradi primerov nsf, o katerih so poročali pri drugih kontrastnih sredstvih, ki vsebujejo gadolinij, in pri gadoversetamidu, ki so lahko povezani z ledvično okvaro, se zdravila optimark pri teh bolnikih ne sme uporabljati.

as there is a possibility that nsf may occur with vasovist, it should therefore only be used in these patients after careful risk/ benefit assessment, and if the diagnostic information cannot be obtained by other means.
obstaja možnost, da se nsf pojavi pri uporabi kontrastnega sredstva vasovist, zato se sme pri teh bolnikih uporabiti le po natančni oceni tveganja in koristi in če se diagnoze ne da postaviti na drug način.